CoagulopathyNCT07043556
Assessment of Artificial Intelligence Algorithms for ROTEM
An observational study of Coagulopathy, run by Ondokuz Mayıs University at 2 sites in Turkey (Türkiye).
Trial summary
The goal of this observational validation study is to evaluate whether artificial intelligence (AI) models can accurately interpret ROTEM (Rotational Thromboelastometry) data and provide appropriate treatment recommendations in adult patients undergoing elective cardiac or liver transplantation surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coagulopathy
- What is being tested?
- Artificial Intelligence-Based ROTEM Interpretation
- How many people
- 0 participants
- Where
- 2 sitesTurkey (Türkiye)
- Study dates
- 1 Jul 2025to 15 Mar 2026
- How long will I take part?
- 30 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: The study population consists of adult patients (aged 18 years and older) undergoing elective cardiac surgeries-including coronary artery bypass grafting (CABG), valve surgery, and aortic procedures-and elective liver transplantation procedures. All participants will have complete and analyzable intraoperative ROTEM (Rotational Thromboelastometry) data available. Only patients who are able to provide written informed consent will be enrolled. Emergency cases, pediatric patients, and those with technically invalid ROTEM results will be excluded.
Who may be able to join
- Adult patients undergoing elective cardiac surgery (CABG, valve surgery, aortic procedures)
- Adult patients undergoing liver transplantation
- Availability of complete ROTEM results (EXTEM, INTEM, FIBTEM, +/- HEPTEM, APTEM)
- Informed written consent obtained
Who cannot join
- Incomplete or technically invalid ROTEM data
- Pediatric patients (<18 years)
- Refusal to participate or lack of informed consent
- Emergency and redo surgeries
Trial locations and contacts
2 sites in 1 country.
Turkey (Türkiye)2 sites
İstanbul Aydın Üniversitesi Sağlık Uygulama ve Araştırma Merkezi Medical Park Florya Hastanesi
Istanbul
Ondokuz Mayis University
Samsun
About this study
Official title: Assessment of Artificial Intelligence Algorithms for ROTEM Analysis in Coagulation Management
The goal of this observational validation study is to evaluate whether artificial intelligence (AI) models can accurately interpret ROTEM (Rotational Thromboelastometry) data and provide appropriate treatment recommendations in adult patients undergoing elective cardiac or liver transplantation surgery.
The main questions it aims to answer are:
Read more
Can AI models (e.g., ChatGPT and Gemini ) accurately determine whether treatment is indicated based on ROTEM parameters? Can AI models correctly identify the type of coagulopathy (e.g., fibrinogen deficiency, platelet dysfunction)? Are the treatment recommendations from AI models concordant with expert clinical consensus? Researchers will compare the decisions made by AI models to a gold standard expert panel to see if AI models can match or approximate expert-level decision-making in interpreting ROTEM outputs.
Participants will:
Undergo elective cardiac or liver transplant surgery. Have standard ROTEM tests performed intraoperatively.
Have their anonymized ROTEM data reviewed independently by:
A panel of 3 clinical experts. AI models (ChatGPT and Gemini) using standardized prompts and ROTEM interpretation guidelines.
Read the detailed description
Rotational thromboelastometry (ROTEM) is a point-of-care viscoelastic testing method used to assess the coagulation status of patients undergoing high-risk surgical procedures, such as cardiac surgery and liver transplantation. While ROTEM-guided transfusion algorithms have improved clinical outcomes, the accurate interpretation of ROTEM results remains complex and heavily dependent on clinical experience.
This prospective observational validation study aims to assess the accuracy and clinical decision-making performance of artificial intelligence (AI)-based language models in interpreting ROTEM findings. The study will compare the AI-based evaluations to expert consensus in terms of both diagnostic accuracy and treatment recommendations.
De-identified ROTEM case data will be converted into structured clinical vignettes, which will be independently interpreted by at least three experienced clinicians (serving as the gold standard) and AI models. Each AI system will be prompted with ROTEM parameters in a standardized format and asked to assess coagulopathy type and suggest appropriate treatment options. ROTEM interpretation algorithms, such as Görlinger's protocol, will be provided as background context to ensure consistent guidance.
The study will include adult patients (≥18 years) undergoing elective cardiac surgery or liver transplantation, provided complete and technically valid ROTEM results are available. The main outcome of the study is the agreement between AI-based and expert decisions regarding the need for treatment. Secondary outcomes include diagnostic classification of coagulopathy, concordance in treatment recommendations, and standard accuracy metrics (sensitivity, specificity, PPV, NPV, overall accuracy, and Cohen's Kappa).
This study does not involve any direct patient interventions or changes in treatment based on AI output. All data will be anonymized before analysis, and informed consent will be obtained from all participants.
As part of the AI evaluation and expert comparison, each ROTEM clinical scenario will be assessed based on a standardized set of 14 structured clinical questions. These questions are designed to determine both the presence and type of coagulopathy, as well as the appropriate treatment recommendations. The specific questions are:
Is there evidence of coagulopathy based on the ROTEM findings?
Do the ROTEM results indicate hyperfibrinolysis?
Do the findings suggest the presence of residual heparin effect?
Is there evidence of fibrinogen deficiency?
Is there evidence of thrombocytopenia or platelet dysfunction?
Do the results indicate coagulation factor deficiency?
Do the findings suggest protamine overdose?
Is treatment not required at this time?
Is antifibrinolytic therapy indicated?
Should protamine be administered?
Should fibrinogen or fibrinogen-containing products be administered?
Should platelet transfusion be performed?
Should prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) be administered?
If bleeding continues, should reassessment be done after 10-15 minutes?
Each question will be answered as "Yes" or "No" by both the AI system and the expert panel, and the responses will be used to calculate diagnostic and treatment concordance metrics.
- Conditions
- Coagulopathy
- Being tested
- Artificial Intelligence-Based ROTEM Interpretation
- Medical subject headings
- Hemostatic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Artificial Intelligence-Based ROTEM InterpretationOther
A structured artificial intelligence-based evaluation system that analyzes ROTEM (Rotational Thromboelastometry) parameters and provides treatment recommendations. ROTEM case data are converted into standardized clinical scenarios and evaluated by AI models using a predefined template. The AI output is compared to the consensus of expert clinicians regarding the presence and type of coagulopathy and the need for therapeutic intervention (e.g., fibrinogen, protamine, platelets, PCC, plasma). This intervention does not involve any patient-facing activity and is performed on de-identified data only.
What is being measured
The primary outcome is the main question the study is designed to answer.
treatment
Agreement (yes/no) between AI model and expert panel on whether treatment is indicated.
Measured: 1 hour
Secondary outcomes (2)
Agreement on Type of Coagulopathy as Determined by ROTEM Analysis Between AI Model and Expert Panel
Agreement on type of coagulopathy
Measured: 1 Hour
Concordance of ROTEM-Based Treatment Recommendations Between AI and Expert Panel
Concordance of treatment recommendations (fibrinogen, PCC, plasma, protamine, etc.)
Measured: 1 Hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2025
- Study start1 Jul 2025
- Primary completion5 Jan 2026 (estimated)
- Study completion15 Mar 2026 (estimated)
Why it stopped: The study was stopped because it was considered unlikely that the required number of patients could be prospectively recruited across the participating study centers.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CoagulopathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
- Target duration
- 30 Days
Sponsor and investigators
- Lead sponsor
- Ondokuz Mayıs University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, BURHAN DOST, Ondokuz Mayıs University
- Investigators
- Burhan Dost, Assoc. Prof., Principal investigator, Ondokuz Mayıs University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07043556
- Sponsor's protocol ID
- ROTEM-AI
- Status last verified
- Jun 2026
- First submitted
- 21 Jun 2025
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD), including demographic characteristics, surgical category, and ROTEM parameter values, may be shared upon reasonable request and at the discretion of the corresponding author. Requests will be evaluated based on the scientific validity of the proposal and availability of resources. No personal identifiers will be included, and data will be provided only after the publication of study results.
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Artificial Intelligence Algorithms for ROTEM Analysis in Coagulation Management
- ClinicalTrials.gov ID
- NCT07043556
- Acronym / sponsor ID
- ROTEM-AI
- Conditions
- Coagulopathy
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: The study was stopped because it was considered unlikely that the required number of patients could be prospectively recruited across the participating study centers.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Ondokuz Mayıs UniversityUniversity, hospital or other
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 5 Jan 2026 (estimated)
- Study completion
- 15 Mar 2026 (estimated)
- First posted
- 29 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational validation study is to evaluate whether artificial intelligence (AI) models can accurately interpret ROTEM (Rotational Thromboelastometry) data and provide appropriate treatment recommendations in adult patients undergoing elective cardiac or liver transplantation surgery.
The main questions it aims to answer are:
Can AI models (e.g., ChatGPT and Gemini ) accurately determine whether treatment is indicated based on ROTEM parameters? Can AI models correctly identify the type of coagulopathy (e.g., fibrinogen deficiency, platelet dysfunction)? Are the treatment recommendations from AI models concordant with expert clinical consensus? Researchers will compare the decisions made by AI models to a gold standard expert panel to see if AI models can match or approximate expert-level decision-making in interpreting ROTEM outputs.
Participants will:
Undergo elective cardiac or liver transplant surgery. Have standard ROTEM tests performed intraoperatively.
Have their anonymized ROTEM data reviewed independently by:
A panel of 3 clinical experts. AI models (ChatGPT and Gemini) using standardized prompts and ROTEM interpretation guidelines.
Detailed description
Rotational thromboelastometry (ROTEM) is a point-of-care viscoelastic testing method used to assess the coagulation status of patients undergoing high-risk surgical procedures, such as cardiac surgery and liver transplantation. While ROTEM-guided transfusion algorithms have improved clinical outcomes, the accurate interpretation of ROTEM results remains complex and heavily dependent on clinical experience.
This prospective observational validation study aims to assess the accuracy and clinical decision-making performance of artificial intelligence (AI)-based language models in interpreting ROTEM findings. The study will compare the AI-based evaluations to expert consensus in terms of both diagnostic accuracy and treatment recommendations.
De-identified ROTEM case data will be converted into structured clinical vignettes, which will be independently interpreted by at least three experienced clinicians (serving as the gold standard) and AI models. Each AI system will be prompted with ROTEM parameters in a standardized format and asked to assess coagulopathy type and suggest appropriate treatment options. ROTEM interpretation algorithms, such as Görlinger's protocol, will be provided as background context to ensure consistent guidance.
The study will include adult patients (≥18 years) undergoing elective cardiac surgery or liver transplantation, provided complete and technically valid ROTEM results are available. The main outcome of the study is the agreement between AI-based and expert decisions regarding the need for treatment. Secondary outcomes include diagnostic classification of coagulopathy, concordance in treatment recommendations, and standard accuracy metrics (sensitivity, specificity, PPV, NPV, overall accuracy, and Cohen's Kappa).
This study does not involve any direct patient interventions or changes in treatment based on AI output. All data will be anonymized before analysis, and informed consent will be obtained from all participants.
As part of the AI evaluation and expert comparison, each ROTEM clinical scenario will be assessed based on a standardized set of 14 structured clinical questions. These questions are designed to determine both the presence and type of coagulopathy, as well as the appropriate treatment recommendations. The specific questions are:
Is there evidence of coagulopathy based on the ROTEM findings?
Do the ROTEM results indicate hyperfibrinolysis?
Do the findings suggest the presence of residual heparin effect?
Is there evidence of fibrinogen deficiency?
Is there evidence of thrombocytopenia or platelet dysfunction?
Do the results indicate coagulation factor deficiency?
Do the findings suggest protamine overdose?
Is treatment not required at this time?
Is antifibrinolytic therapy indicated?
Should protamine be administered?
Should fibrinogen or fibrinogen-containing products be administered?
Should platelet transfusion be performed?
Should prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) be administered?
If bleeding continues, should reassessment be done after 10-15 minutes?
Each question will be answered as "Yes" or "No" by both the AI system and the expert panel, and the responses will be used to calculate diagnostic and treatment concordance metrics.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 30 Days
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The study population consists of adult patients (aged 18 years and older) undergoing elective cardiac surgeries-including coronary artery bypass grafting (CABG), valve surgery, and aortic procedures-and elective liver transplantation procedures. All participants will have complete and analyzable intraoperative ROTEM (Rotational Thromboelastometry) data available. Only patients who are able to provide written informed consent will be enrolled. Emergency cases, pediatric patients, and those with technically invalid ROTEM results will be excluded.
Key inclusion criteria (4 listed)
- Adult patients undergoing elective cardiac surgery (CABG, valve surgery, aortic procedures)
- Adult patients undergoing liver transplantation
- Availability of complete ROTEM results (EXTEM, INTEM, FIBTEM, +/- HEPTEM, APTEM)
- Informed written consent obtained
Key exclusion criteria (4 listed)
- Incomplete or technically invalid ROTEM data
- Pediatric patients (<18 years)
- Refusal to participate or lack of informed consent
- Emergency and redo surgeries
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Artificial Intelligence-Based ROTEM InterpretationA structured artificial intelligence-based evaluation system that analyzes ROTEM (Rotational Thromboelastometry) parameters and provides treatment recommendations. ROTEM case data are converted into standardized clinical scenarios and evaluated by AI models using a predefined template. The AI output is compared to the consensus of expert clinicians regarding the presence and type of coagulopathy and the need for therapeutic intervention (e.g., fibrinogen, protamine, platelets, PCC, plasma). This intervention does not involve any patient-facing activity and is performed on de-identified data only. | Other | – |
Primary outcome
treatment
Time frame: 1 hour
Agreement (yes/no) between AI model and expert panel on whether treatment is indicated.
2 secondary outcomes
Agreement on Type of Coagulopathy as Determined by ROTEM Analysis Between AI Model and Expert Panel
Time frame: 1 Hour
Concordance of ROTEM-Based Treatment Recommendations Between AI and Expert Panel
Time frame: 1 Hour
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD), including demographic characteristics, surgical category, and ROTEM parameter values, may be shared upon reasonable request and at the discretion of the corresponding author. Requests will be evaluated based on the scientific validity of the proposal and availability of resources. No personal identifiers will be included, and data will be provided only after the publication of study results.
Related trials for Coagulopathy
RecruitingPhase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Immune Thrombocytopenia
RecruitingPhase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
RecruitingPhase 3
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Essential Thrombocythemia
RecruitingPhase 1
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Not yet recruitingPhase 1
Lentiviral FVIII Gene Therapy
Hemophilia A
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Burhan Dost, Assoc. Prof. principal investigator
Ondokuz Mayıs University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coagulopathy, run by Ondokuz Mayıs University at 2 sites in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
treatment (time frame: 1 hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.